Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 23, 2025
Company Drug

J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication

Fineline Cube Dec 23, 2025
Company Drug

Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD

Fineline Cube Jan 17, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...

Company Deals

AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab

Fineline Cube Jan 17, 2023

China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...

Policy / Regulatory

China’s NHC Releases Second National Drug Use Monitoring List

Fineline Cube Jan 17, 2023

China’s National Health Commission (NHC) has released the second national drug use monitoring list, covering...

Company Deals

Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion

Fineline Cube Jan 17, 2023

China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds...

Company Deals

Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion

Fineline Cube Jan 17, 2023

Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance...

Company Drug

CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers

Fineline Cube Jan 17, 2023

CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...

Company Deals

Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development

Fineline Cube Jan 17, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...

Company Drug

Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA

Fineline Cube Jan 17, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...

Company Drug

Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China

Fineline Cube Jan 17, 2023

US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...

Company Drug

Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication

Fineline Cube Jan 17, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...

Company Medical Device

Agilis Robotics Completes Successful Animal Testing for Surgical Robot

Fineline Cube Jan 17, 2023

Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...

Company Deals

CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China

Fineline Cube Jan 17, 2023

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...

Company Deals

Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China

Fineline Cube Jan 17, 2023

China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...

Company Drug

3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jan 16, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...

Company Drug

Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11

Fineline Cube Jan 16, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...

Company Deals

Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines

Fineline Cube Jan 16, 2023

Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...

Company Deals

ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline

Fineline Cube Jan 16, 2023

ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...

Company Drug

Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder

Fineline Cube Jan 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...

Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Posts pagination

1 … 507 508 509 … 600

Recent updates

  • Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval
  • J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
  • Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
  • Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
  • IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Company Drug

J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication

Company Drug

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Company Drug

Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.